ABSTRACT:
This article aims to review existing evidence and evaluate the documented reasons of high association of Mucormycosis with Covis-19 patients. A literature search was conducted using CDC, MedlinePlus, PubMed, Medscape and Researchgate databases.
Cite this article:
Neha Abhishek Sharma. Mucormycosis: Why Incidence Rate is more in Covid -19 patients. Asian Journal of Nursing Education and Research. 2021; 11(4):599-0. doi: 10.52711/2349-2996.2021.00139
Cite(Electronic):
Neha Abhishek Sharma. Mucormycosis: Why Incidence Rate is more in Covid -19 patients. Asian Journal of Nursing Education and Research. 2021; 11(4):599-0. doi: 10.52711/2349-2996.2021.00139 Available on: https://ajner.com/AbstractView.aspx?PID=2021-11-4-31
REFERENCES:
1. https://www.ncbi.nlm.nih.gov/books/NBK544364/
2. https://pubmed.ncbi.nlm.nih.gov
3. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED)
4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases external icon. Clin Infect Dis. 2005 Sep 1;41(5):634-53.
5. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of Mucormycosis external icon. Clin Infect Dis. 2012 Feb;54 Suppl 1: S23-34.
6. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated Mucormycosis (zygomycosis) external icon. Clin Infect Dis. 2012 Feb;54 Suppl 1:S55-60.